Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesus F San Miguel

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2013
Induction therapy for newly diagnosed multiple myelomaSagar Lonial, Jesus F San Miguel
Advances in Therapy|September 29, 2016
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveJesus F San-Miguel, Hermann Einsele, Philippe Moreau
Nature Reviews. Clinical Oncology|August 2, 2012
Haematological cancer: Redefining myelomaS Vincent Rajkumar, Giampaolo Merlini, Jesus F San Miguel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2022
Reply to I.V. Kostopoulos et alJuan-Jose Garcés, Jesus F San-Miguel, Bruno Paiva
Cancer Cell|September 17, 2015
Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T CellsJesus F San Miguel, Bruno Paiva, Juan-Jose Lasarte
Blood|August 15, 2015
Guidelines for determination of the number of prior lines of therapy in multiple myelomaS Vincent Rajkumar, Paul Richardson, Jesus F San Miguel
European Journal of Haematology|October 15, 2010
Emerging therapies for the treatment of relapsed or refractory multiple myelomaMeletios A Dimopoulos, Jesus F San-Miguel, Kenneth C Anderson
Blood|October 29, 2009
How I treat multiple myeloma in younger patientsA Keith Stewart, Paul G Richardson, Jesus F San-Miguel
Expert Opinion on Investigational Drugs|May 25, 2012
Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDsEnrique M Ocio, Maria-Victoria Mateos, Jesus F San-Miguel
Hematology (Amsterdam, Netherlands)|April 18, 2012
Multiple myeloma: treatment evolutionJesus F San Miguel, Maria Victoria Mateos, Enrique Ocio, et al.
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2013
Induction therapy for newly diagnosed multiple myelomaSagar Lonial, Jesus F San Miguel
Advances in Therapy|September 29, 2016
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveJesus F San-Miguel, Hermann Einsele, Philippe Moreau
Nature Reviews. Clinical Oncology|August 2, 2012
Haematological cancer: Redefining myelomaS Vincent Rajkumar, Giampaolo Merlini, Jesus F San Miguel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2022
Reply to I.V. Kostopoulos et alJuan-Jose Garcés, Jesus F San-Miguel, Bruno Paiva
Cancer Cell|September 17, 2015
Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T CellsJesus F San Miguel, Bruno Paiva, Juan-Jose Lasarte
Blood|August 15, 2015
Guidelines for determination of the number of prior lines of therapy in multiple myelomaS Vincent Rajkumar, Paul Richardson, Jesus F San Miguel
European Journal of Haematology|October 15, 2010
Emerging therapies for the treatment of relapsed or refractory multiple myelomaMeletios A Dimopoulos, Jesus F San-Miguel, Kenneth C Anderson
Blood|October 29, 2009
How I treat multiple myeloma in younger patientsA Keith Stewart, Paul G Richardson, Jesus F San-Miguel
Expert Opinion on Investigational Drugs|May 25, 2012
Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDsEnrique M Ocio, Maria-Victoria Mateos, Jesus F San-Miguel
Hematology (Amsterdam, Netherlands)|April 18, 2012
Multiple myeloma: treatment evolutionJesus F San Miguel, Maria Victoria Mateos, Enrique Ocio, et al.
Pageof 11